Reading a Newspaper

News

 

ZiP Diagnostics Presents at AusMedtech 2022

May 2022

ZiP Diagnostics made its first conference appearance at the recent AusMedtech 2022.

AusMedtech was a two-day conference (25-26 May) which showcased Australia's flourishing medtech network. There were over 450 Australian and international delegates present to discuss this year's theme of 'Medtech and Manufacturing'.

There was significant interest at the ZiP Diagnostics' booth, with delegates keen to see an Australian-made molecular point-of-care test platform. All main components of the test have been designed, developed and manufactured in Melbourne. ZiP's PC2 laboratory and manufacturing clean rooms are based in Collingwood.

The ZiP-CoVx-P2 test provides a point-of-care result for SARS-CoV-2 within 30 minutes. Clinical trials are currently underway and aims to have performance equivalent to lab-based PCR. Regulatory submissions to Australia's TGA and Europe's IVDR are in preparation.

ZiP representatives in attendance: Mr. Bill Hopper (Technical Director), Dr. Hanh Nguyen (Research Officer), Dr. Khashayar Farrokzhad (Senior Research Officer), and Ms. An Le (System Scientist).

 
 

ZiP has secured a prestigious grant from the British Society of Antimicrobial Chemotherapy (BSAC) to assess its new COVID point-of-care test in Ghana

October 2020

Doctor Charles Narh, who leads the genetics and bioinformatics team at ZiP, will lead the BSAC field validation project. Doctor Narh, who studied for his PhD at the University of Melbourne, is originally from Ghana and has extensive field experience in researching and implementing programs for infectious diseases in Ghana. The project will partner with Dr Lydia Mosi and colleagues at the Noguchi Memorial Institute for Medical Research and the West African Centre for Cell Biology of Infectious Pathogens, who is spearheading Ghana’s response to the COVID-19 pandemic.

ZiP has recently developed a low-cost and easy to use point-of-care COVID-19 test that delivers a result in less than 30 minutes. It provides high sensitivity detection of active infection with SARS-CoV-2 virus, comparable to the polymerase chain reaction (PCR) laboratory test. The objective of ZiP’s point-of-care platform is to provide real time access to test results and a test capability that can be used at a community level without the need for a laboratory.​ 

“We are delighted to receive this BSAC grant as it provides valuable assistance with funding for the validation and implementation of ZiP’s technology in my home country of Ghana, which at this stage is not adversely affected by COVID-19.” said Doctor Narh.

ZiP Awarded $750k Commercialisation Grant

April 2021

ZiP Diagnostics has been announced as one of the successful recipients of the Department of Industry, Science and Technology, Accelerating Commercialisation grants scheme, receiving $750,000 to establish manufacturing facilities for customised protein production and commercialisation of low cost, high sensitivity molecular diagnostic tests. 

The Minister specifically identified two projects that had impressive health benefits and outstanding commercial potential. ZiP was one of these with the Minister stating “… the ZiP system promises to vastly reduce the amount of time required for infectious diseases results to be confirmed…”

Dr Jack Richards, ZiP Scientific Director, was very pleased to receive the grant, “This grant will provide ZiP with important funding to ramp-up our Collingwood production facility and to provide a unique domestic capability to produce low-cost novel point-of-care molecular diagnostics for infectious diseases, including COVID-19, for Australia and world markets."

ZiP secures $600k federal grant for COVID-19 test

19 July 2020

Federal Minister for Health, the Hon Greg Hunt, made the announcement today, revealing details of the third round of grants from the $45 million BioMedTech Horizons (BMTH) program.

“We are delighted to receive this BMTH grant as it provides valuable funding for the development of ZiP’s technology and will allow us to secure regulatory approval in a shorter time frame than originally envisaged,” said ZiP Technical Director Bill Hopper.

All key elements of the ZiP technology are made locally ensuring Australia is less susceptible to global supply chain issues for diagnostic equipment. The test regime is suitable for use across many industry and community sectors including government, health, travel, defence, education, mining, industrial, commercial and sport.

“This innovative technology and our local production capacity means ZiP is ideally placed to play a major role in the identification, containment and management of COVID-19 in Australia,” Mr Hopper said.

ZiP starts pre-clinical testing of SARS-CoV-2 test system

June 2020

ZiP started pre-clinical testing of its SARS-CoV-2 test system at Royal Melbourne Hospital with the Victorian Infectious Diseases Reference Laboratory (VIDRL) in early June 2020. Pre-clinical testing is being conducted to complete commercial development of the system. 

ZiP is planning to apply for Therapeutic Goods Administration, TGA approval for its SARS-CoV-2 test systems in 2021 with validation of its at scale production facilities.

FIND contract for CT-NG development

October 2019

Axxin supported by ZiP Diagnostics have been awarded a contract with the Geneva-based Foundation for Innovative New Diagnostics (FIND) to develop and commercialise a CT-NG (chlamydia and gonorrhoea) point-of-care test system. 

The Phase 1 proof-of-concept work required rigorous pre-clinical testing including extensive sensitivity and specific testing. The testing was conducted in collaboration with the Victorian Infectious Diseases Reference Laboratory (VIDRL). The success of this work has led to awarding of a phase 2 diagnostic contract. 

ZiP intends to deliver a product for clinical trials in 2021.